Find the perfect market access consultant.
Start a ProjectOther content in this Stream
The lines are blurring between U.S. healthcare payers and providers. What does this payer/provider consolidation mean for pharma? Nothing less than a total shift in the way it does business. If...
Get expert advice and seasoned project managers for all your market access, value, and reimbursement initiatives.
Innovation is at the heart of the life sciences industry. BTG has the hands and minds you need to make it happen.
The pharmaceutical reimbursement landscape has grown increasingly complex and—thanks to an intensifying focus on improving clinical outcomes—increasingly competitive. Reimbursement was once a...
It’s not easy to bring a new drug to market. As corporate market access functions evolve to help life science companies streamline the complex process of getting therapies into patients’ hands,...
Prescription drug affordability is a major concern in health and life science—and not just in the U.S. Mounting drug costs have put huge strains on global health systems and have contributed to a...
The head of the medical products division at a F200 healthcare company was concerned about stagnating profits in the U.S. She had identified 15 different countries that presented growth...
Affordability is a major concern in health and life science—and not just in the U.S. In 2018, total prescription drug expenditure in the U.S. is expected to top $520 billion; 52% of Americans say...
A F300 pharma company was preparing to launch a new oncology drug. But its understaffed pricing and market access group was struggling to create global access plans and strategies. Expecting...
Payer pressure is rising, and regulatory structures are growing more complex around the globe. So it’s no surprise that life sciences companies are trying to formalize the way they address these...
A major biopharmaceutical company had developed a breakthrough medication that stood to dramatically disrupt the market for its therapeutic area. Expected to be approved by the FDA in the next...
It can be hard to find the right talent to manage critical initiatives—especially when trying to find a life science consultant. In the life science industry, 70% of CEOs say they are concerned...
The lean market access group at a global pharma company was preparing to launch a recently acquired pipeline oncology asset. Yet they were struggling to coordinate US payer marketing activities....
25 of the top 30 Life Sciences companies work with Business Talent Group on high-impact projects. These projects range from R&D to commercialization and performance improvement–and have made Life...
At BTG, we help clients address all sorts of business problems. Here are 3 of the most interesting challenges we saw this September… Pricing and Tender Strategy The head of the medical products...
Having robust, nimble market access strategies is increasingly important in life sciences. It’s also increasingly challenging, with fast-changing markets, increased patient engagement, and global...
At BTG, we help clients address all sorts of business problems. Here are 3 of the most interesting challenges we saw this July… Launching a new drug As the launch date for a major new drug drew...
The VP of Global Marketing at a F200 pharma company was reviewing a promising drug about to enter Phase II of R&D. The company’s lean team had already completed a broad indication assessment, but...
